RxDoctor Payments Data

Douglas Birch

Podiatrist · Kahului, HINPI 1033113071

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations.

$1,221in general payments, 2019–2025

Across 40 payments — averaging $30.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$228
  • Orthofix Medical, Inc.$222
  • Abbott$122
  • Stryker$88
  • Anika Therapeutics, Inc.$88
  • Amgen$79
  • plus $394 from 9 others

What the payments were for

  • Food & beverage$1,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few podiatrist providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$154,144
Medicare patients
520
Services billed
1,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam161$1,031
Pregabalin12$866
Celecoxib25$456
Gabapentin25$376
Terbinafine Hcl23$241
Mupirocin15$214
Methylprednisolone29$203
Doxycycline Hyclate29$185
Cephalexin20$144
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$59
Ciprofloxacin Hcl13$58

Paid to pharmacies, not to this prescriber.

Other podiatrist in Kahului

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →